News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

Author(s)Kirollos S. Hanna, PharmD, BCPS, BCOP, Hope Rugo, MD, Joyce O’Shaughnessy, MD

A medical expert navigates toxicity management in patients being treated with ribociclib.

Episodes in this series

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 3 Outcomes from NATALEE and MonarchE

EP. 3 Outcomes from NATALEE and MonarchE

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

A panel of 4 experts on breast cancer

EP. 5 Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

A panel of 4 experts on breast cancer

EP. 6 Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

A panel of 4 experts on breast cancer

EP. 7 Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

A panel of 4 experts on breast cancer

EP. 8 Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

A panel of 4 experts on breast cancer

EP. 9 Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 10 How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

A panel of 4 experts on breast cancer

EP. 11 Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 12 Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

A panel of 4 experts on breast cancer

EP. 13 ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

How do you monitor for and manage hematologic toxicities seen with ribociclib?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

FDA approved | Image: Adobe Stock

FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations

September 4th 2026

Housing inequity | Image credit: Pix_Std - stock.adobe.com

Historical Redlining Linked to Lower Breast Cancer Screening

ByPearl Steinzor

September 2nd 2026

Adaptive Trials Cut Time to Effective Breast Cancer Therapies: Laura Esserman, MD, MBA

ByGiuliana Grossi,Laura Esserman, MD, MBA,

August 18th 2026

Tiffany Meng, PharmD

ADCs and Oral SERDs Reshape Breast Cancer Pharmacy Role: Tiffany Meng, PharmD

ByGiuliana Grossi,Tiffany Meng, PharmD

August 18th 2026

Lidia Schapira, MD

Adapting Breast Cancer Therapy to the Individual, Not Just the Scan: Lidia Schapira, MD

ByGiuliana Grossi,Lidia Schapira, MD, FASCO

August 14th 2026

Trending on AJMC

Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show

Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials

Fragmented Care, Financial Strain, Gender Gaps Define Life With COPD

AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans

Trump Admin Awards $106M to Expand Rural Health Care in NY, RI, MI